在临床实践中使用无创检测识别非酒精性脂肪性肝炎高危患者的实用方法
该文由NASH专家小组基于已验证无创检测(NIT)的风险分层证据,提出一个三步算法,用于在初级保健、内分泌科和消化科实践中识别非酒精性脂肪性肝病(NAFLD)高危患者。第一步用临床数据识别可能进展性NAFLD风险患者,第二步计算FIB-4评分进一步分层低风险者并由初级保健提供者管理其心脏代谢合并症,第三步使用二线NIT(瞬态弹性成像或增强肝纤维化检测)识别进展性肝病高风险者并应考虑由具备NASH专长的提供者进行专科护理。结论认为该简单临床算法可识别并协助管理NAFLD不良结局高危患者。
要点
- 第一步用临床数据(如2型糖尿病或代谢综合征多重组分)识别可能进展性NAFLD风险患者。
- 第二步计算FIB-4评分,将低进展性肝病风险者交由初级保健提供者管理其心脏代谢合并症。
- 第三步使用二线NIT(瞬态弹性成像或增强肝纤维化检测)识别高进展性肝病风险者,应考虑由具备NASH专长的提供者进行专科护理。
核心结论
- 使用该简单临床算法可识别并协助管理NAFLD不良结局高危患者。
研究设计与样本
- 由NASH专家小组对已验证NIT用于NAFLD风险分层的证据进行综述,并基于最新证据开发算法。
主要发现
- 提出的算法采用三步流程识别NAFLD患者中可能不良结局高危者。
- 第一步使用临床数据识别大多数有潜在进展性NAFLD风险的患者(如患有T2D或代谢综合征多重组分)。
- 第二步计算FIB-4评分作为NIT,进一步对进展性肝病低风险个体进行风险分层,这些个体可由其初级保健提供者管理心脏代谢合并症。
- 第三步使用二线NIT(瞬态弹性成像或增强肝纤维化检测)识别进展性肝病高风险者,应考虑由具备NASH专长的提供者进行专科护理。
关键数值与推荐
- 第一步:使用临床数据(如T2D或代谢综合征多重组分)识别潜在进展性NAFLD风险患者。
- 第二步:计算FIB-4评分,对进展性肝病低风险者由初级保健提供者管理其心脏代谢合并症。
- 第三步:使用二线NIT(瞬态弹性成像或增强肝纤维化检测)识别进展性肝病高风险者,应考虑由具备NASH专长的提供者进行专科护理。
临床怎么用
- 在初级保健、内分泌科和消化科实践中,可按三步算法对NAFLD患者进行风险分层。
- 低风险个体可由初级保健提供者管理其心脏代谢合并症。
- 高风险个体应考虑由具备NASH专长的提供者进行专科护理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D) or other components of metabolic syndrome are at high risk for disease progression. We proposed an algorithm to identify high-risk NAFLD patients in clinical practice using noninvasive tests (NITs). METHODS: Evidence about risk stratification of NAFLD using validated NITs was reviewed by a panel of NASH Experts. Using the most recent evidence regarding the performance of NITs and their application in clinical practice were used to develop an easy-to-use algorithm for risk stratification of NAFLD patients seen in primary care, endocrinology and gastroenterology practices. RESULTS: The proposed algorithm uses a three-step process to identify NAFLD patients who are potentially at high risk for adverse outcomes. The first step is to use clinical data to identify most patients who are at risk for having potentially progressive NAFLD (e.g. having T2D or multiple components of metabolic syndrome). The second step is to calculate the FIB-4 score as a NIT that can further risk stratifying individuals who are at low risk for progressive liver disease and can be managed by their primary healthcare providers to manage their cardiometabolic comorbidities. The third step is to use second-line NITs (transient elastography or enhanced liver fibrosis tests) to identify those who at high risk for progressive liver disease and should be considered for specially care by providers with NASH expertise. CONCLUSIONS: The use of this simple clinical algorithm can identify and assist in managing patients with NAFLD at high risk for adverse outcomes.
引用
- Younossi Z, Alkhouri N, Cusi K, et al. A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2022. PMID: 36511349. doi:10.1111/apt.17346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。